Impaired insulin clearance and insulin resistance are germane to anti-tumor therapy because pharmacological inhibition of insulin-signaling (i.e., GLUT4 stimulation) decreases tumor glucose uptake, thereby limiting substrate availability for growth [14, 54, 56]. The gene discussed is SLC2A4; the disease is neoplasm.